Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA

BACKGROUND: Radium‐223 prolongs overall survival in patients with castration‐resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel. Whether or not chemotherapy can be safely administered following radium‐223 treatment is of clinical importance. An explorator...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate
Autors principals: Sartor, Oliver, Hoskin, Peter, Coleman, Robert E., Nilsson, Sten, Vogelzang, Nicholas J., Petrenciuc, Oana, Staudacher, Karin, Thuresson, Marcus, Parker, Christopher
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5071661/
https://ncbi.nlm.nih.gov/pubmed/27004570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.23180
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars